Education
About Us
Working with TipRanks
Follow Us
Leap Therapeutics (LPTX)
:LPTX
LPTX Stock Chart & Stats
$0.52
-$0.03(-0.86%)
At close: 4:00 PM EST
$0.52
-$0.03(-0.86%)
Day’s Range― - ―
52-Week Range― - ―
Previous CloseN/A
Volume72.74K
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)$9.69M
Total Debt (Recent Filing)$38.00K
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Mar 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)3.09
Price to Sales (P/S)0.00
P/FCF Ratio-1.79
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentPromising efficacy data point to market potential of DNK-01 in approximately 25%-50% of 2L patients.
Financial StabilityThe company reported approximately $47M in cash and cash equivalents at the end of 4Q24, which is believed to be sufficient to fund operations.
Bears Say
Pipeline DevelopmentUncertainties regarding the company's pipeline development and lack of meaningful catalysts contribute to the Neutral rating on LPTX.
Strategic PartnershipsThe company still needs to identify a partner to run the registrational Phase 3 study.
Leap Therapeutics News
LPTX FAQ
What was Leap Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Leap Therapeutics’s market cap?
Currently, no data Available
When is Leap Therapeutics’s upcoming earnings report date?
Leap Therapeutics’s upcoming earnings report date is Mar 23, 2026 which is in 92 days.
How were Leap Therapeutics’s earnings last quarter?
Leap Therapeutics released its earnings results on Nov 12, 2025. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.24 by $0.16.
Is Leap Therapeutics overvalued?
According to Wall Street analysts Leap Therapeutics’s price is currently Overvalued.
Does Leap Therapeutics pay dividends?
Leap Therapeutics does not currently pay dividends.
What is Leap Therapeutics’s EPS estimate?
Leap Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Leap Therapeutics have?
Currently, no data Available
What happened to Leap Therapeutics’s price movement after its last earnings report?
Leap Therapeutics reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.24. Following the earnings report the stock price went up 365.909%.
Which hedge fund is a major shareholder of Leap Therapeutics?
Currently, no hedge funds are holding shares in LPTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Technical Analysis
Imunon
―
XTL Biopharmaceuticals Sponsored ADR
―
Carisma Therapeutics
―
MetaVia
―
Allarity Therapeutics
―
Ownership Overview
Currently, No data available
---